- Home
- TVTX
as 11-17-2025 3:43pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.1B | IPO Year: | N/A |
| Target Price: | $37.21 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.91 - $36.76 | Next Earning Date: | 10-30-2025 |
| Revenue: | $435,826,000 | Revenue Growth: | 114.22% |
| Revenue Growth (this year): | 108.68% | Revenue Growth (next year): | 40.23% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Nov 4 '25 | Sell | $36.00 | 67,115 | $2,416,140.00 | 48,545 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Oct 31 '25 | Sell | $35.00 | 5,591 | $195,685.00 | 119,071 | |
| COUGHLIN TIMOTHY | TVTX | Director | Oct 31 '25 | Sell | $35.03 | 18,000 | $630,601.20 | 55,500 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Oct 29 '25 | Sell | $30.12 | 27,128 | $817,073.66 | 419,173 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Oct 28 '25 | Sell | $30.38 | 92,872 | $2,821,358.49 | 419,173 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Oct 28 '25 | Sell | $30.00 | 2,662 | $79,860.00 | 119,071 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Sep 22 '25 | Sell | $25.00 | 10,000 | $250,000.00 | 89,878 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 4 '25 | Sell | $19.71 | 119 | $2,345.49 | 92,083 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 3 '25 | Sell | $18.20 | 454 | $8,262.80 | 92,083 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Aug 27 '25 | Sell | $17.31 | 470 | $8,135.70 | 92,083 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Investor's Business Daily
2 months ago
Hims & Hers Leads 15 Growth Stocks Amid Medical Boom
Business Wire
2 months ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
2 months ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Insider Monkey
2 months ago
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Zacks
2 months ago
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Investor's Business Daily
2 months ago
Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High
Simply Wall St.
2 months ago
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.